QLIFE HOLDING AB, Interim Report Q3, July - September 2026

The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter

Financial summary - third quarter 2026

Revenue in the period amounted to kSEK 0 (65).

· EBIT for the period amounted to kSEK -3,927 (-6,716 ), and net loss kSEK -3,932 (-6,974).

· The total cash flow in the third quarter amounted to kSEK -2,797 (2,336  ).

· Earnings per share before/after dilution for the quarter amounted to SEK -0.19 (-0.75), calculated on weighted average number of shares in the period.

Significant events - third quarter of 2026

• On 17. July 2026 Qlife provides business update for the first half of 2026. The company emphasises that it has diligently worked to advance multiple strategic partnership initiatives across both pharmaceutical and diagnostics sectors, while maintaining steady progress on its Egoo Health platform and regulatory milestones.
• On 29. September Qlife announces the successful completion of a customer-funded feasibility study focused on evaluating the applicability of the Egoo® platform within a new therapeutic area requiring regular biomarker monitoring. The parties will continue discussions around a broader product development program.

Significant events - after the third quarter of 2026

• On 14. October Qlife informs that the United States Patent and Trademark Office (USPTO) has approved the Company's U.S. patent application covering core Egoo platform technology for issuance. The approval establishes patent protection for key elements of the platform in the United States and further strengthens Qlife's global intellectual property position.
• On 23. October Qlife announces that it has received ISO 13485 certification covering its at-home blood testing solution for PHE related to the Phenylketonuria condition, marking an important regulatory and quality milestone for the company and its Egoo Health platform. To Qlife's knowledge, this represents a unique certification scope within at-home PHE testing.
• On 11. November Qlife announces that it is entering a partner-financed product-readiness phase with its pharmaceutical partner aimed at a clinical development and commercialisation partnership. The pharmaceutical partner will finance the product-readiness phase with SEK 2.7 million, and has already financed the initial feasibility phase with SEK 1.5 million.

Letter from the CEO

From product-readiness to commercialization

Q3 marks an important step in Qlife's journey from developing diagnostic technology to becoming a commercial partner and product supplier to the pharmaceutical industry.

Our ongoing pharmaceutical collaboration is moving into the next level: a focused product-readiness phase. This program consists of a 12-week technical phase followed by four weeks of preparation for formal product development. The work is designed to prepare and perform the complete testing workflow and enable an efficient transition into a clinical and commercialisation partnership.

Our goal together with our pharmaceutical partner is to develop a diagnostic product that can become an integral part of how patients are tested and monitored when treated with the partner's pharmaceutical product. Following successful regulatory approval and commercial launch, Qlife will enter a licensing agreement and become the long-term supplier of the Egoo systems and tests needed to support the therapy.

The real commercial opportunity starts with licensing and supply

The greater long-term opportunity is what follows after the clinical programs and regulatory approval, when Qlife's role evolve to become a licensing, commercial- and supply partner for an essential companion diagnostic as part of the patient journey. In many ways, that is when the commercial opportunity really begins.

Throughout the development, clinical and registration phase activities will be cash positive for Qlife and as the therapy reaches patients, Qlife would generate licensing fees and recurring revenues from supplying Egoo systems and tests. The scale of this business would be linked to the number of patients, the installed base of Egoo systems and how frequently patients need to be tested.

The pathway is clear:

Product-readiness → Clinical validation → Regulatory approval → Licensing agreement and commercial launch → Long-term supply → Recurring revenues

Successfully progressing along this pathway would move Qlife towards a commercial supplier of diagnostic products at scale to the pharmaceutical industry.

From one partnership to a repeatable model

The strategic opportunity extends beyond this individual program.

We see the current collaboration as a potential blueprint for future pharmaceutical partnerships, some of which are already under consideration:

1. Identify an important biomarker need connected to a therapy.
2. Adapt Egoo to the specific application.
3. Develop and validate the product together with the pharmaceutical partner.
4. Become the long-term supplier of the decentralized testing solution.

Modern therapies increasingly depend on biomarker information. Testing may be needed to select the right patients, start treatment, adjust the dose, monitor safety or measure whether the treatment is working.

Egoo has been designed to bring this testing and information closer to the patient.

We therefore see an opportunity for Egoo to become a general companion diagnostic platform providing decentralized testing and treatment-monitoring platform for pharmaceutical therapies. This could make biomarker testing an integral part of how treatments are delivered and managed, increasingly closer to the patient and, over time, in the home.

One platform, multiple partnerships

Our ambition is to repeat this model across additional pharmaceutical partners, biomarkers and therapeutic areas.

Importantly, these programs can use the same core Egoo infrastructure. Each successful collaboration can add a new application, a new pharmaceutical relationship and potentially a new recurring supply stream.

This is where we see the scalability of Egoo:

One platform. Multiple pharmaceutical partners. Multiple therapies. Multiple diagnostic applications. Recurring licensing fees and revenues from testing.

Over time, our aim is to build a portfolio of pharmaceutical partnerships that combine partner-funded product development with long-term commercial supply.

The company we are building

Our immediate priority is clear: successfully complete the current product-readiness project and prepare for the transition into the larger formal clinical and commercialisation partnership.

But our ambition is reaching further.

We want successful development programs to become long-term commercial licensing- and supply relationships. We then want to repeat this model across the pharmaceutical industry.

To sum up: Our ambition is to establish Egoo as a platform that enables pharmaceutical companies to integrate decentralized companion diagnostic testing directly into their therapies - closer to patients and increasingly into the home.

If we execute successfully, Qlife can develop from a diagnostic technology company into a scalable pharmaceutical diagnostics partner and product supplier. This would combine development revenues with long-term, recurring revenues from licensing and commercial testing.

The current program is an important step towards making that transition real.

Thomas Warthoe

Göteborg, 11, November 2026